Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — NANETS 2026
17 slides from Perspective Therapeutics's conference presentation, Nov 6, 2026
Slide 1: NANETS 2026 Presentation: Bamzireotide navoxetan
PERSPECTiVE’ THERAPEUTICS Investor Presentation NANETS 2026 Presentation Bamzireotide navoxetan : Emerging Best-in-Class Potential in SSTR2+ NETs NYSE AMERICAN: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: GEP-NETs Next Opportunity is for Deeper and More Durable Disease Control
INVESTOR CONTEXT | GEP-NET GEP-NETs Next Opportunity is for Deeper and More Durable Disease Control WHERE PATIENTS ARE TODAY 1L SSA backbone Octreotide / lanreotide Qe Post-SSA options Lutathera * Everolimus « Sunitinib (pNET) * Cabozantinib + non-approved (e.g. CAPTEM) Treatment selection and seque
Slide 4: Bamzireotide Navoxetan Addresses a Large SSTR2+ Population
NEUROENDOCRINE TUMORS Bamzireotide Navoxetan Addresses a Large SSTR2+ Population ~2 50 K | “A 1 2 K 90% © Room for a Next-Generation Alpha RLT 212; ahiohe People living with NETs in the U.S.t of GEP-NETs express SSTR2? ° Pb alpha payload: high energy, And newly diagnosed annual in the U.S.2 short-ra
Slide 5: Phase 1/2a is Defining a Broad Therapeutic Window Across Multiple Doses
STUDY DESIGN Phase 1/2a is Defining a Broad Therapeutic Window Across Multiple Doses Dose-Finding Study in Radiotherapy Naive, SSTR2 Positive Patients Median follow up 34 (11-59) weeks Cohort 3 o poroorecrr treet 6.0 mCi x 4 (=24 mCi) H n= 20 Median follow up 76 (6-124) weeks Cohort 2 Cohort 4 Front
Slide 6: Bamzireotide navoxetan is being evaluated in a broader, less selected SSTR2 population
INVESTOR CONTEXT | GEP-NET Bamzireotide navoxetan is being evaluated in a broader, less selected SSTR2 population Three phase 3 PRRT benchmarks used distinct populations; Bamzireotide navoxetan combines progressive disease with broader biology and SSTR2 heterogeneity PROGRESSIVE | SELECTED EARLY-LIN
Slide 7: Robust Disease Control and Encouraging Objective Responses Observed Across Cohorts 2 and 3
NANETS 2026 DATA Robust Disease Control and Encouraging Objective Responses Observed Across Cohorts 2 and 3 Objective Responses (PR + uPR) in Cohort 2 (33%) and Cohort 3 (50%), with disease control in 289% of patients in each cohort - Best overall response by cohort 50% Cohort 1 | Cohort 2 | Cohort
Slide 8: Serial Tumor Assessments Support Sustained Antitumor Activity
NANETS 2026 DATA Serial Tumor Assessments Support Sustained Antitumor Activity SSTR2+ GEP-NET patients: Durable ongoing disease control Cohort 2, subjects who received at least 1 dose Cohort 3, subjects who received at least 1 dose 75 75 i a Percent Change from Baseline (%) o Percent Change from Bas
Slide 9: Durable Ongoing Disease Control
NANETS 2026 DATA Durable Ongoing Disease Control Cohorts 1-3, All subjects receiving at least 1 dose (N=68) 0 20 40 Study Week 60 © Cohort 1 © Cohort 2 © Cohort 3 © Not GEP-NET or 21 non-SSTR2 target lesion A First Response A\ Confirmed PR [] Disease progression Death 80 100 Darker segment of each b
Slide 10: Durable Ongoing Disease Control
NANETS 2026 DATA Durable Ongoing Disease Control Cohorts 1-3, All subjects receiving at least 1 dose (N=68) > © Cohort 1 Cohort 2 © Cohort 3 A First Response A\ Confirmed PR [] Disease progression Death 20 40 60 80 100 Study Week 10 | Darker segment of each bar represents treatment period. Lighter s
Slide 11: Maturing PFS Supports Translation into Durable Clinical Benefit
NANETS 2026 DATA Maturing PFS Supports Translation into Durable Clinical Benefit Across SSTR2+ GEP-NET patients in Cohort 1-3 (N=57)* The Kaplan-Meier estimate of investigator-assessed PFS at 18 months was 75.1% ort 2 89.5% 76.1% 73.2% PFS at 6 months PFS at 12 months PFS at 18 months Kaplan-Meier e
Slide 12: Favorable Ongoing Safety Profile Strengthens the Therapeutic-Index Thesis
NANETS 2026 DATA Favorable Ongoing Safety Profile Strengthens the Therapeutic-Index Thesis Most common TEAEs (215%), % of patients Safety analysis set: Cohorts 1-3 (N = 68) No DLTs in DLT-evaluable patients Alopecia Nausea No TEAEs leading to treatment discontinuation Fatigue TEAEs mostly Grade 1-2;
Slide 13: Renal Monitoring Shows No Clear Evidence of Broad Toxicity Signal
NANETS 2026 DATA Renal Monitoring Shows No Clear Evidence of Broad Toxicity Signal Serum creatinine (mg/dL) — Cohorts 1, 2 and 31 5 . ” Grade 3 renal events were rare (2/68 patients) during _4 ongoing study follow up, possibly not drug related* a 3 2 3 * Both occurred in patients during study follow
Slide 14: Bamzireotide navoxetan is showing a differentiated early safety profile in GEP-NET
INVESTOR CONTEXT | GEP-NET Bamzireotide navoxetan is showing a differentiated early safety profile in GEP-NET No evidence of excess renal or marrow toxicity to date relative to known SSTR2-RLT benchmarks How VMT-a-NET safety profile compares across the Bamzireotide navoxetan RLT landscape : —T 5 VMT
Slide 15: Three dimensions provide a strong foundation for a registrational study
INVESTOR CONTEXT | GEP-NET Three dimensions provide a strong foundation for a registrational study Strong biological, clinical and therapeutic-index data strengthen our confidence to test translation of this effect in a controlled Phase 3 study. 01 BIOLOGICAL? 37% | 47% Reproducible responses across
Slide 16: Appendix
PERSPECTIVE’ ~~" @ THERAPEUTICS Appendix NYSE AMERICAN: CATX
Slide 17: Radioligand Therapy Trials in SSTR2+ GEP-NETs
APPENDIX Radioligand Therapy Trials in SSTR2+ GEP-NETs Study Status Dose (administered) Prior PRRT Histology (61/G2/G3) Median PFS ‘ORR Grade 23 Any Grade AEs > treatment discontinuations Any Grade AEs > treatment modification or interruptions Renal (All /G 2 3) (*Timeframe beyond treatment period)